Projected lifetime healthcare costs associated with HIV infection

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Nakagawa, Fumiyo ^a   Miners, Alec ^b   Smith, Colette J ^a   Simmons, Ruth ^c   Lodwick, Rebecca K ^a   Cambiano, Valentina ^a   Lundgren, Jens D ^d   Delpech, Valerie ^c   Phillips, Andrew N ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; GENERIC DRUG; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE TRANSMISSION; DRUG POTENCY; GENOTYPE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVENTION STUDY; LIFE EXPECTANCY; MEN WHO HAVE SEX WITH MEN; MORTALITY; SENSITIVITY ANALYSIS; SIMULATION; SMOKING; STOCHASTIC MODEL; TREATMENT OUTCOME; UNITED KINGDOM; VIRUS LOAD; ECONOMIC MODEL; ECONOMICS; HIV INFECTIONS; PATENT;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUGS, GENERIC; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; MODELS, ECONOMIC; PATENTS AS TOPIC;

EID: 84930627632     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125018     Document Type: Article

References (32)

1. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352(9142):1725-1730. PMID: 9848347
2. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338(13):853-860. PMID: 9516219
3. May MT, Gompels M, Delpech V, Porter K, Post F, Johnson M, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ 2011; 343:d6016. doi: 10.1136/bmj.d6016 PMID: 21990260
4. Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012; 26(3):335-343.
5. Yin Z, Brown AE, Hughes G, Nardone A, Gill ON, Delpech VC & contributors. HIV in the United Kingdom 2014 Report: data to end 2013. November 2014. Public Health England, London, UK.
6. Phillips AN, Sabin C, Pillay D, Lundgren JD. HIV in the UK 1980-2006: Reconstruction using a model of HIV infection and the effect of antiretroviral therapy. HIV Med 2007; 8(8):536-546. PMID: 17944687
7. Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, et al. Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. HIV Med 2010; 11(7):432-438. doi: 10.1111/j.1468-1293.2009.00809.x PMID: 20146736
8. Office for National Statistics. Deaths registered in England and Wales (Series DR), 2011. Available: www.ons.gov.uk. Accessed: 13 August 2013.
9. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338:a3172. doi: 10.1136/bmj.a3172 PMID: 19171560
10. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008; 22(18):2409-2418. doi: 10.1097/QAD.0b013e3283174636 PMID: 19005264
11. Health Protection Agency. HIV in the United Kingdom: 2012 Report. London: Health Protection Services, Colindale. November 2012.
12. Harding R, Bensley J, Corrigan N. Targeting smoking cessation to high prevalence communities: outcomes from a pilot intervention for gay men. BMC Public Health 2004; 4(1):1-5.
13. Hagger-Johnson G, Taibjee R, Semlyen J, Fitchie I, Fish J, Meads C, et al. Sexual orientation identity in relation to smoking history and alcohol use at age 18/19: cross-sectional associations from the Longitudinal Study of Young People in England (LSYPE). BMJ Open 2013; 3:e002810. doi: 10.1136/bmjopen-2013-002810 PMID: 23985386
14. Kuller LH, Ockene JK, Meilahn E, Wentworth DN, Svendsen KH, Neaton JD. Cigarette-Smoking and Mortality. Preventive Medicine 1991; 20(5):638-654. PMID: 1758843
15. Daskalopolou M, Rodger A, Phillips AN, Sherr L, Speakman A, Collins S, et al. Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: results from the cross-sectional ASTRA study. The Lancet HIV 2014; 1(1):e22-e31.
16. Turner J, Bansi L, Gilson R, Gazzard B, Walsh J, Pillay D, et al. The Prevalence of Hepatitis C Virus (HCV) Infection in HIV-positive Individuals in the UK-Trends in HCV Testing and the Impact of HCV on HIV Treatment Outcomes. J Viral Hepat. 2010; 17(8):569-577.
17. Beck EJ, Mandalia S, Sangha R, Sharott P, Youle M, Baily G, et al. The Cost-Effectiveness of Early Access to HIV Services and Starting cART in the UK 1996-2008. PLoS ONE 2011; 6(12):e27830. doi: 10.1371/journal.pone.0027830 PMID: 22194795
18. Department of Health. HIV Outpatient services tariff development. Gateway Reference 15869. Available: http://webarchive.nationalarchives.gov.uk/. Accessed: 7 November 2011
19. Kanavos P. Do generics offer significant savings to the UK National Health Service? Curr Med Res Opin 2006; 23(1):105-116.
20. Gazzard B, Moecklinghoff C, Hill A. New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom. Clinicoecon Outcomes Res 2012; 4:193-200. doi: 10.2147/CEOR.S12496 PMID: 22888265
21. Lampe FC, Smith CJ, Madge S, Loes SKD, Tyrer M, Sabin CA, et al. Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med 2007; 167(7):692-700. PMID: 17420428
22. Lampe FC, Gatell JM, Staszewski S, Johnson MA, Pradier C, Gill MJ, et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy - A multicohort analysis, 1996 to 2002. Arch Intern Med 2006; 166(5):521-528. PMID: 16534038
23. O'Connor J, Smith C, Lampe F, Johnson M, Sabin C, Phillips A. Rate of viral load failure over time in people on ART in the UK Collaborative HIV Cohort (CHIC) study. Journal of the International AIDS Society 2014, 17(Suppl 3):19527 doi: 10.7448/IAS.17.4.19527 PMID: 25394036
24. Rao G, Sutton S, Hardin J, Bennett C. Impact of highly active antiretroviral therapy regimen on adherence and risk of hospitalization in veterans with HIV/AIDS. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, Colorado. 10-13 September 2013. Abstract H-1464.
25. Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to Antiretroviral Treatment and Correlation with Risk of Hospitalization among Commercially Insured HIV Patients in the United States. PLoS ONE 2012; 7(2):e31591. doi: 10.1371/journal.pone.0031591 PMID: 22384040
26. Arribas J, Clumeck N, Nelson M, Hill A, van Delft Y, Moecklinghoff C. The MONET trial: week 144 analysis of efficacy of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs, for patients with HIV RNA < 50 copies/mL at baseline. HIV Med 2013; 13(7):398-405.
27. Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, Girard PM, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010; 24(15):2365-2374. doi: 10.1097/QAD.0b013e32833dec20 PMID: 20802297
28. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006; 44(11):990-997. PMID: 17063130
29. Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackman BR, et al. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS 2012; 26(1):45-56.
30. Yazdanpanah Y, Goldie SJ, Losina E, Weinstein MC, Lebrun T, Paltiel AD, et al. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther 2002; 7(4):257-266. PMID: 12553480
31. Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, et al. Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States. Ann Intern Med 2013; 158(2):84-92. doi: 10.7326/0003-4819-158-2-201301150-00002 PMID: 23318310
32. Paltiel AD, Weinstein MC, Kimmel AD, Seage GR, Losina E, Zhang H, et al. Expanded screening for HIV in the United States - An analysis of cost-effectiveness. N Engl J Med 2005; 352(6):586-595. PMID: 15703423